4 completed. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Lung Infection: new trials by email Literature Review of Lung Infection trials Research Report on Lung Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection AP-PA02, Placebo - Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa | Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 48 | 2023-01-10 | 2026-01-05 |
| Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis AP-PA02, Placebo - Cystic Fibrosis, Pseudomonas Aeruginosa | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 29 | 2020-12-22 | 2024-01-31 |
| Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia Opaganib, Placebo - COVID-19, Lung Infection | Phase 2 / Phase 3 | Completed | RedHill Biopharma Limited | 475 | 2020-08-21 | 2025-07-31 |
| Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection Aztreonam for Inhalation (AI), Placebo - Cystic Fibrosis, CF | Phase 2 | Completed | Gilead Sciences | 105 | 2003-06-01 | 2010-01-26 |
Pseudomonas Infections (3) · Cystic Fibrosis (2) · COVID-19 (1)
Infections (4) · Bacterial Infections (3) · Bacterial Infections and Mycoses (3) · Gram-Negative Bacterial Infections (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Genetic Diseases, Inborn (2) · Infant, Newborn, Diseases (2) · Pancreatic Diseases (2) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Nidovirales Infections (1) · Pneumonia (1)
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (1) · Aztreonam (1) · Inhalation (1)
Armata Pharmaceuticals, Inc. (2) · Gilead Sciences (1) · RedHill Biopharma Limited (1)
United States (4) · Brazil (1) · Colombia (1) · Israel (1) · Italy (1) · Mexico (1) · Peru (1) · Poland (1) · Russia (1) · United Kingdom (1)
George Retsch-Bogart, MD (1) · Mark L Levitt, MD (1) · Mina Pastagia, MD, MS (1) · Ronald L Gibson, Jr., MD (1)